Overview
Alopecia universalis (AU) is the most extensive form of alopecia areata, an autoimmune condition characterized by the complete loss of hair on the entire body. This includes the scalp, eyebrows, eyelashes, beard, axillary hair, pubic hair, and all other body hair. AU is considered the most severe end of the alopecia areata spectrum, which ranges from patchy hair loss (alopecia areata) to total scalp hair loss (alopecia totalis) to complete body hair loss (alopecia universalis). The condition results from an immune-mediated attack on hair follicles, in which T-lymphocytes target the hair bulb, disrupting the normal hair growth cycle. Importantly, the hair follicles are not permanently destroyed, meaning regrowth remains theoretically possible. Alopecia universalis primarily affects the integumentary system (skin and hair). Beyond the cosmetic impact, loss of nasal hair, eyelashes, and eyebrows can increase vulnerability to dust, allergens, and sun exposure around the eyes. Nail changes, including pitting, ridging, and brittleness, may also occur in some patients. The condition can have a profound psychological and emotional impact, affecting quality of life, self-esteem, and social functioning, particularly in children and adolescents. There is a genetic predisposition to alopecia universalis, with associations identified with several HLA genes and other immune-related loci. Treatment options have historically been limited and often unsatisfactory for this severe form. Conventional therapies include topical and systemic corticosteroids, topical immunotherapy (such as diphenylcyclopropenone), and immunosuppressive agents, though response rates in AU are generally lower than in milder forms of alopecia areata. More recently, JAK inhibitors (such as baricitinib, which received FDA approval for severe alopecia areata in 2022) have shown significant promise in promoting hair regrowth in patients with alopecia universalis, representing a major advance in the treatment landscape.
Clinical phenotype terms— hover any for plain English:
Multifactorial
Caused by a mix of several genes and environmental factors
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Alopecia universalis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Alopecia universalis at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Alopecia universalis.
Community
No community posts yet. Be the first to share your experience with Alopecia universalis.
Start the conversation →Latest news about Alopecia universalis
No recent news articles for Alopecia universalis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Alopecia universalis
What is Alopecia universalis?
Alopecia universalis (AU) is the most extensive form of alopecia areata, an autoimmune condition characterized by the complete loss of hair on the entire body. This includes the scalp, eyebrows, eyelashes, beard, axillary hair, pubic hair, and all other body hair. AU is considered the most severe end of the alopecia areata spectrum, which ranges from patchy hair loss (alopecia areata) to total scalp hair loss (alopecia totalis) to complete body hair loss (alopecia universalis). The condition results from an immune-mediated attack on hair follicles, in which T-lymphocytes target the hair bulb,
How is Alopecia universalis inherited?
Alopecia universalis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Which specialists treat Alopecia universalis?
25 specialists and care centers treating Alopecia universalis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.